Efficacy and tolerability of a single-pill combination of telmisartan/ hydrochlorothiazide 80/25 mg in Chinese and Korean patients with moderate to severe hypertension: A subgroup analysis of a randomized, double-blind, active-controlled trial

Chinese Medical Journal

Volumn 126, Issue 21, 2013, Pages 4072-4077

  Zhu, Ding Liang ^a   Gao, Ping Jin ^a   Liu, Shao Wen ^b   Jeong, Myung Ho ^c   Mattheus, Michaela ^d   Voelker, Birgit ^d  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c Chonnam National University Medical School   (South Korea)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Chinese; Hydrochlorothiazide; Hypertension; Korean; Single pill combination; Telmisartan

Indexed keywords

HYDROCHLOROTHIAZIDE PLUS TELMISARTAN; TELMISARTAN;

ABDOMINAL DISCOMFORT; ADULT; AGED; ARTICLE; CAROTID ARTERY OBSTRUCTION; CONSTIPATION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ERECTILE DYSFUNCTION; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE STRAIN; OTITIS MEDIA; PHASE 4 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; THORAX PAIN; THYROID CANCER; TOOTH PAIN; URIC ACID BLOOD LEVEL;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84887101918     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20123345     Document Type: Article

References (31)

1. Martiniuk AL, Lee CM, Lawes CM, Ueshima H, Suh I, Lam TH, et al. Hypertension: its prevalence and population-attributable fraction for mortality from cardiovascular disease in the Asia-Pacific region. J Hypertens 2007; 25: 73-79
2. He J, Gu D, Chen J, Wu X, Kelly TN, Huang JF, et al. Premature deaths attributable to blood pressure in China: a prospective cohort study. Lancet 2009; 374: 1765-1772
3. Cheung BM, Cheung TT. Challenges in the management of hypertension in Asia. Eur Heart J Suppl 2012; 14 Suppl A: A37-A38
4. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252
5. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121-2158
6. NICE. Hypertension: The clinical management of primary hypertension in adults. Clinical Guideline: Methods, evidence and recommendations. (Accessed in December 2011 at www. nice. org. uk/nicemedia/live/12167/53228/53228. pdf)
7. Japanese Society of Hypertension Committee. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009) Chapter 5. Treatment with antihypertensive drugs. Hypertens Res 2009; 32: 3-107
8. Verdecchia P, Angeli F, Gentile G, Mazzotta G, Reboldi G. Telmisartan for the reduction of cardiovascular morbidity and mortality. Expert Rev Clin Pharmacol 2011; 4: 151-161
9. Yu LT, Zhu J, Tan HQ, Wang GG, Teo KK, Liu LS. Telmisartan, ramipril, or both in high-risk Chinese patients: analysis of ONTARGET China data. Chin Med J 2011; 124: 1763-1768
10. Dans AL, Teo K, Gao P, Chen JH, Jae-Hyung K, Yusoff K, et al. In a subgroup of high-risk Asians, telmisartan was non-inferior to ramipril and better tolerated in the prevention of cardiovascular events. PLoS One 2010; 5: e13694
11. Zhu D, Bays H, Gao P, Mattheus M, Voelker B, Ruilope LM. Efficacy and tolerability of initial therapy with single-pill combination telmisartan/hydrochlorothiazide 80/25 mg in patients with grade 2 or 3 hypertension: a multinational, randomized, double-blind, active-controlled trial. Clin Ther 2012; 34: 1613-1624
12. Zhu D, Bays H, Gao P, Mattheus M, Voelker B, Ruilope LM. Efficacy and tolerability of a single-pill combination of telmisartan 80 mg and hydrochlorothiazide 25 mg according to age, sex, race, hypertension severity and previous antihypertensive use: planned analyses of a randomized trial. Integr Blood Press Control 2013; 6: 1-14
13. Mancia G, De BG, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-1187
14. Jo I, Ahn Y, Lee J, Shin KR, Lee HK, Shin C. Prevalence, awareness, treatment, control and risk factors of hypertension in Korea: the Ansan study. J Hypertens 2001; 19: 1523-1532
15. Ma WJ, Tang JL, Zhang YH, Xu YJ, Lin JY, Li JS, et al. Hypertension prevalence, awareness, treatment, control, and associated factors in adults in southern China. Am J Hypertens 2012; 25: 590-596
16. Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009; 32: 3-107
17. Liu Z. Dietary sodium and the incidence of hypertension in the Chinese population: a review of nationwide surveys. Am J Hypertens 2009; 22: 929-933
18. Yoshimura M, Kawai M. Synergistic inhibitory effect of angiotensin II receptor blocker and thiazide diuretic on the tissue renin-angiotensin-aldosterone system. J Renin Angiotensin Aldosterone Syst 2010; 11: 124-126
19. Woo J, Chan TY. A high incidence of cough associated with combination therapy of hypertension with isradipine and lisinopril in Chinese subjects. Br J Clin Pract 1991; 45: 178-180
20. Chan WK, Chan TY, Luk WK, Leung VK, Li TH, Critchley JA. A high incidence of cough in Chinese subjects treated with angiotensin converting enzyme inhibitors. Eur J Clin Pharmacol 1993; 44: 299-300
21. Woo KS, Nicholls MG. High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese. Br J Clin Pharmacol 1995; 40: 141-144
22. Morimoto T, Gandhi TK, Fiskio JM, Seger AC, So JW, Cook EF, et al. Development and validation of a clinical prediction rule for angiotensin-converting enzyme inhibitor-induced cough. J Gen Intern Med 2004; 19: 684-691
23. Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest 2006; 129 (1 Suppl): 169S-173S
24. McDowell SE, Coleman JJ, Ferner RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ 2006; 332: 1177-1181
25. Tseng DS, Kwong J, Rezvani F, Coates AO. Angiotensin-converting enzyme-related cough among Chinese-Americans. Am J Med 2010; 123: 183-185
26. Andrew N, Gabb G, Del FM. ACEI associated angioedema-a case study and review. Aust Fam Physician 2011; 40: 985-988
27. Izzo JL Jr, Weir MR. Angiotensin-converting enzyme inhibitors. J Clin Hypertens (Greenwich) 2011; 13: 667-675
28. Lacourciere Y, Brunner H, Irwin R, Karlberg BE, Ramsay LE, Snavely DB, et al. Effects of modulators of the renin-angiotensin-aldosterone system on cough. Losartan Cough Study Group. J Hypertens 1994; 12: 1387-1393
29. Pylypchuk GB. ACE inhibitor-versus angiotensin II blocker-induced cough and angioedema. Ann Pharmacother 1998; 32: 1060-1066
30. Tolerability and quality of life in ARB-treated patients. Am J Manag Care 2005; 11 (13 Suppl): S392-S394
31. Mancia G, Schumacher H. Incidence of adverse events with telmisartan compared with ACE inhibitors: evidence from a pooled analysis of clinical trials. Patient Prefer Adherence 2012; 6: 1-9